

119. Thibault A, Cooper MR, Figg WD, et al. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. *Cancer Res* 1994; 54: 1690-4
120. Burzynski SR, Stolzmann Z, Szopa B, et al. Antineoplaston A in cancer therapy (I). *Physiol Chem Phys Med NMR* 1977; 9: 485-500
121. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies of oral formulation of antineoplaston A10. *Drugs Exp Clin Res* 1984; 10: 891-909
122. Burzynski SR. Toxicology studies of antineoplaston AS2-5 injections in cancer patients. *Drugs Exp Clin Res* 1986; 12 Suppl. 1: 17-24
123. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies of antineoplaston AS2-1 injections in cancer patients. *Drugs Exp Clin Res* 1986; 12 Suppl. 1: 25-35
124. Burzynski SR, Kubove E. Toxicology studies of antineoplaston A10 injections in cancer patients. *Drugs Exp Clin Res* 1986; 12 Suppl. 1: 47-55
125. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years follow-up. *Drugs Exp Clin Res* 1987; 13 Suppl. 12: 1-12
126. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. *Drugs Exp Clin Res* 1987; 13 Suppl. 1: 37-43
127. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of oral formulations of antineoplaston AS2-1. *Adv Exp Clin Chemother* 1988; 2: 29-36
128. Thibault A. Experimental therapies - CPB, NCI. 1994; 1-8
129. Eriguchi N, Tsuda H, Hara H, et al. The effect of antineoplaston A10, AS2-1 on brain tumor. In: Adam D, editor. Recent advances in chemotherapy. Munich: Futuramed Publishers, 1991
130. Yoshida H, Nishida H, Kitsuu T, et al. Effect of antineoplastons on multiple brain metastases. *J Jpn Soc Cancer Ther* 1992; 27: 1943-9
131. Tsuda H, Sugita Y, Sugita N, et al. Effect of antineoplaston AS2-1 on high grade glioma. Eighteenth International Congress on Chemotherapy: 1993 Jun 27-Jul 2; Stockholm
132. van der Schaaf PJ. Antineoplaston therapy in a private out-patient environment. Eighteenth International Congress on Chemotherapy: 1993 Jun 27-Jul 2; Stockholm
133. Burzynski SR. Treatment of malignant brain tumors with antineoplastons. *Adv Exp Clin Chemother* 1988; 6: 45-56
134. Burzynski SR, Kubove E, Burzynski B. Phase II clinical trials of antineoplastons A10 and AS2-1 infusions in astrocytoma. In: Adam D, editor. Recent advances in chemotherapy. Munich: Futuramed Publishers, 1992
135. Burzynski SR, Kubove E, Szymkowski B. Phase II clinical trials of antineoplaston A10 and AS2-1 infusions in high grade glioma. Eighteenth International Congress on Chemotherapy: 1993 Jun 27-Jul 2; Stockholm
136. Antineoplastons: request for Phase II trials in CNS malignancies. CTEP Letter: rapid communication request for letters of Intent. Vol. 10: 10, NCI, DCT, CTEP, 1992
137. Miller RA. Aging and immune function. *Int Rev Cytol* 1991; 124: 187-215
138. Zhou D, Chrest FJ, Adler W, et al. Age-related changes in the expression of the TGF- receptor on CD4+ and CD8+ subsets of T-cells. *Aging Immunol Infect Dis* 1992; 3: 217-26
139. De Greef GE, Van Staelduinen GJ, Van Doorninck H, et al. Age-related changes of the antigen-specific antibody formation in vitro and PHA-induced T-cell proliferation in individuals who met the health criteria of the Senieur protocol. *Mech Ageing Dev* 1992; 66: 1-14
140. Saini A, Sei Y. Age-related impairment of early and late events of signal transduction in mouse immune cells. *Life Sci* 1993; 52: 1759-65
141. Beeson PB. Age and sex associations of 40 autoimmune diseases. *Am J Med* 1994; 96: 457-62
142. Linos A, Worthington JW, O'Fallon WM, et al. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. *Am J Epidemiol* 1980; 111: 87-98
143. Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis in demographic subsets. *Medicine* 1985; 64: 285-95
144. Wallace DJ. Active idiopathic systemic lupus erythematosus in a 90 year old woman requiring corticosteroid therapy. *J Rheumatol* 1991; 18: 1611-2
145. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. *Nature* 1983; 304: 177-9
146. Mathews MB, Reichlin M, Hughes GRV, et al. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. *J Exp Med* 1984; 160: 420-34
147. Sinha AA, Lopez MT, McDevitt HO. Autoimmune diseases: the failure of self tolerance. *Science* 1990; 248: 1380-8
148. Burzynski SR. Methods for treating autoimmune diseases. U.S. Patent Application No. 07/898295
149. Gatti RA, Boder E, Vinters HV, et al. Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. *Medicine* 1991; 70: 99-117
150. Waldmann TA, Misiti J, Nelson DL, et al. Ataxia-telangiectasia: a multisystem hereditary disease with immunodeficiency, impaired organ maturation, x-ray hypersensitivity, and a high incidence of neoplasia. *Ann Intern Med* 1983; 99: 367-79
151. Lin LH, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science* 1993; 260: 1130-2
152. Hyman C, Hoger M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. *Nature* 1991; 350: 230-2
153. Korsching S. The neurotrophic factor concept: a reexamination. *J Neurosci* 1993; 13: 2739-48
154. Isackson PJ, Murray KD. Neurotrophic factors in the treatment of Alzheimer's disease. *Drug News and Perspectives* 1994; 7: 585-92
155. Olson L. NGF and the treatment of Alzheimer's disease. *Exp Neurol* 1993; 124: 5-15
156. Weiss R. Promising protein for Parkinson's. *Science* 1993; 260: 1072-3
157. Burzynski SR. Methods for treating Parkinson's disease. US Patent No. 5116622
158. Juskiewicz M, Chodkowska A, Burzynski SR, et al. The influence of antineoplaston A5 on the central dopaminergic structures. *Drugs Exp Clin Res* 1994; 20: 161-7
159. Harris JE. The treatment of cancer in an aging population. *JAMA* 1992; 268: 96-7
160. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. *N Eng J Med* 1995; 332: 143-9
161. Weinberg K, Parkmann R. Age, the thymus, and T-lymphocytes. *N Eng J Med* 1995; 332: 182-3
162. Tsuda H, Sugihara S, Nishida H, et al. The characteristics of inhibitory effect of antineoplaston A10 injection on human tumor cells. Ninth International Symposium on Future Trends in Chemotherapy: 1990 Mar 26-28; Geneva